psoriatic arthritis
Rheumatology · 2006–2026
56decisions
17medicines
24carried consumer input
26individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| ustekinumab Treatment of adult patients with severe chronic plaque psoriasis and severe psoriatic arthritis. | Mar 2026 | Recommended | unclear |
| etanercept General Schedule Authority Required and Section 100 (Highly Specialised Drugs Program) Authority Required listings for severe psoriatic arthritis, ankylosing… | Jul 2025 | Recommended with restriction | none received |
| infliximab Rheumatoid arthritis, psoriatic arthritis, Crohn's disease (adults and children 6-17 years), refractory Crohn's disease, ankylosing spondylitis, psoriasis, and… | Jul 2025 | Recommended with restriction | input received Colitis Australia |
| infliximab Biosimilar to reference infliximab for multiple indications: rheumatoid arthritis, psoriatic arthritis, Crohn's disease (adults and children/adolescents 6–17… | Mar 2025 | Recommended with restriction | input received Australasian Society of Clinical Immunology and Allergy |
| infliximab Continuing treatment and balance of supply of infliximab 120 mg subcutaneous injection for ankylosing spondylitis, severe Crohn disease, severe chronic plaque… | Mar 2025 | Recommended with restriction | input received Australasian Society of Clinical Immunology and Allergy |
| ustekinumab Biosimilar to Stelara for severe chronic plaque psoriasis, severe psoriatic arthritis, severe Crohn disease, complex refractory fistulising Crohn disease, and… | Mar 2025 | Recommended | input received |
| adalimumab Biosimilar adalimumab for multiple indications including severe Crohn disease, moderate to severe ulcerative colitis, severe active juvenile idiopathic… | Jul 2024 | Recommended with restriction | none received |
| bimekizumab Severe active psoriatic arthritis in adult patients without an adequate response to conventional disease-modifying anti-rheumatic drugs (cDMARDs). | Mar 2024 | Recommended with restriction | input received CreakyJoints Australia |
| tofacitinib Treatment of severe active rheumatoid arthritis (RA) and severe psoriatic arthritis (PsA) in adults. The modified-release 11 mg once-daily tablet is requested… | Mar 2024 | Recommended with restriction | input received CreakyJoints Australia · Global Healthy Living Foundation Australia |
| ustekinumab Treatment of paediatric severe chronic plaque psoriasis, severe Crohn disease, moderate to severe ulcerative colitis, complex refractory fistulising Crohn… | Mar 2024 | Recommended with restriction | input received Colitis Australia |
| ustekinumab Severe chronic plaque psoriasis (adult and paediatric), severe psoriatic arthritis, severe Crohn disease, complex refractory fistulising Crohn disease, and… | Nov 2024 | Recommended with restriction | input received Colitis Australia |
| apremilast Severe active psoriatic arthritis in patients who have previously failed to achieve an adequate response to conventional synthetic disease modifying… | Mar 2023 | Not recommended | input received Musculoskeletal Australia · Australian Rheumatology Association |
| infliximab Treatment of ankylosing spondylitis (AS), severe chronic plaque psoriasis (CPP), severe active psoriatic arthritis (PsA), and complex refractory fistulising… | Mar 2022 | Recommended | unclear |
| risankizumab Treatment of severe psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs). | Mar 2022 | Recommended with restriction | input received Creaky Joints Australia |
| adalimumab; upadacitinib Change in restriction levels (Authority Required categories) for adalimumab across multiple indications (rheumatoid arthritis, ankylosing spondylitis,… | Nov 2022 | Noted | 1 individuals |
| adalimumab Biosimilar to Humira for multiple indications including severe Crohn disease, moderate to severe ulcerative colitis, severe active rheumatoid arthritis, severe… | Jul 2021 | Recommended with restriction | input received |
| etanercept Severe active rheumatoid arthritis, severe psoriatic arthritis, ankylosing spondylitis, severe chronic plaque psoriasis, and severe active juvenile idiopathic… | Jul 2021 | Recommended | unclear |
| upadacitinib Severe active psoriatic arthritis in patients who have failed to achieve an adequate response to conventional disease modifying anti-rheumatic drugs (cDMARDs). | Mar 2021 | Recommended with restriction | none received |
| etanercept Biosimilar to Enbrel for severe active rheumatoid arthritis, severe psoriatic arthritis, ankylosing spondylitis, severe chronic plaque psoriasis, and juvenile… | Nov 2021 | Recommended with restriction | unclear |
| adalimumab Biosimilar to adalimumab for multiple indications including severe Crohn disease, complex refractory fistulising Crohn disease, moderate to severe ulcerative… | Jul 2020 | Recommended with restriction | none received |
| adalimumab Biosimilar to Humira for multiple indications including severe Crohn disease, moderate to severe ulcerative colitis, severe active juvenile idiopathic… | Mar 2020 | Recommended | input received Colitis Australia |
| etanercept Administrative request to change listing restrictions and authority level for etanercept biosimilar (Brenzys) to support biosimilar uptake in rheumatoid… | Dec 2020 | Not recommended | no section in document |
| adalimumab Multiple indications including severe Crohn disease, moderate to severe ulcerative colitis, severe active juvenile idiopathic arthritis, complex refractory… | Nov 2020 | Recommended with restriction | input received Colitis Australia |
| guselkumab Treatment of severe psoriatic arthritis (PsA) in adult patients who have failed to respond to methotrexate, sulfasalazine, or leflunomide. | Nov 2020 | Recommended with restriction | 1 individuals Creaky Joints Australia |
| infliximab Treatment of severe active rheumatoid arthritis, moderate to severe ulcerative colitis, and severe refractory Crohn's disease in adult patients via… | Nov 2020 | Recommended with restriction | input received Colitis Australia |
| infliximab Increase in maximum quantity from 4 to 5 vials for subsequent continuing treatment of severe Crohn disease, complex refractory fistulising Crohn disease,… | Mar 2019 | Recommended with restriction | 3 individuals |
| adalimumab Biosimilar of adalimumab for all indications for which Humira is currently PBS listed, including severe active rheumatoid arthritis, severe psoriatic… | Jul 2018 | Recommended with restriction | 1 individuals |
| ixekizumab Treatment of severe active psoriatic arthritis in adults who have responded inadequately or are intolerant to previous DMARD therapy. | Jul 2018 | Recommended with restriction | 3 individuals |
| abatacept Treatment of severe active psoriatic arthritis (PsA) in patients who have failed to achieve an adequate response to non-biologic disease-modifying… | Mar 2018 | Not recommended | 11 individuals CreakyJoints Australia · Psoriasis Australia |
| etanercept Severe active rheumatoid arthritis, severe psoriatic arthritis, ankylosing spondylitis, severe chronic plaque psoriasis, juvenile severe chronic plaque… | Mar 2018 | Recommended with restriction | none received |
| etanercept Changes to the listing of etanercept (Brenzys brand) to support biosimilar uptake, including modifications to authority requirements and treatment cycle… | Nov 2018 | Deferred | none received |
| tofacitinib Severe active psoriatic arthritis in patients with inadequate response to conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs). | Nov 2018 | Recommended with restriction | none received |
| etanercept Severe active rheumatoid arthritis, ankylosing spondylitis, severe psoriatic arthritis, and severe chronic plaque psoriasis. | Aug 2017 | Recommended with restriction | no section in document |
| certolizumab pegol Treatment of severe active rheumatoid arthritis, severe psoriatic arthritis, and active ankylosing spondylitis. | Mar 2017 | Recommended with restriction | none received |
| infliximab Change to initial and continuing treatment restrictions for infliximab biosimilar, and application of biosimilar uptake measures for multiple indications… | Nov 2017 | Recommended with restriction | none received |
| etanercept Biosimilar etanercept for all indications for which etanercept (Enbrel) is currently PBS-listed: rheumatoid arthritis, ankylosing spondylitis, psoriatic… | Jul 2016 | Recommended with restriction | input received |
| certolizumab pegol Loading dose administration in patients with ankylosing spondylitis, severe psoriatic arthritis, and severe active rheumatoid arthritis to reduce patient… | Mar 2016 | Recommended | no section in document |
| secukinumab Treatment of severe active psoriatic arthritis in patients meeting certain criteria, including those who have failed conventional synthetic DMARDs. | Mar 2016 | Recommended with restriction | none received |
| infliximab Biosimilar infliximab for the same indications as Remicade: rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis, ulcerative colitis,… | Nov 2016 | Recommended with restriction | none received |
| infliximab Biosimilar to Remicade, indicated for rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis, ulcerative colitis, and Crohn's disease. | Jul 2015 | Recommended with restriction | 2 individuals |
| ustekinumab Treatment of adult patients with psoriatic arthritis who have inadequate response to previous non-biological DMARD therapy, administered alone or in… | Jul 2015 | Not recommended | 4 individuals |
| apremilast Severe active psoriatic arthritis in patients who have previously received and failed to achieve an adequate response to one or more disease modifying… | Mar 2015 | Not recommended | none received |
| apremilast Treatment of severe active psoriatic arthritis (PsA) in adult patients. | Nov 2015 | Not recommended | input received |
| ustekinumab Treatment of psoriatic arthritis (PsA) in adult patients. | Nov 2015 | Recommended with restriction | none received |
| certolizumab pegol Treatment of psoriatic arthritis (PsA) in adult patients with active disease where response to previous disease-modifying anti-rheumatic drugs (DMARDs) is… | Nov 2014 | Recommended with restriction | none received |
| ustekinumab Treatment of psoriatic arthritis (PsA) in patients who have failed therapy with standard DMARDs. | Nov 2014 | Not recommended | none received |
| golimumab Treatment of adult patients with severe active psoriatic arthritis when the response to previous disease-modifying anti-rheumatic drug therapy has been… | Mar 2010 | Recommended with restriction | no section in document |
| golimumab Treatment of adult patients with severe active psoriatic arthritis. | Mar 2010 | Recommended with restriction | no section in document |
| etanercept Extension to PBS listing for rheumatoid arthritis (RA) and psoriatic arthritis (PsA) to include patients with ≥10 tender and swollen joints or ≥2 major… | Jul 2008 | Not recommended | no section in document |
| etanercept Extension of PBS listing for rheumatoid arthritis (RA) and psoriatic arthritis (PsA) to include patients with ≥10 tender and swollen joints or ≥2 major… | Jul 2008 | Not recommended | no section in document |
| leflunomide Active psoriatic arthritis in patients for whom other disease modifying anti-rheumatic drugs (including methotrexate) are inappropriate or ineffective. | Mar 2007 | Recommended with restriction | no section in document |
| leflunomide Treatment of active psoriatic arthritis in patients for whom other disease modifying anti-rheumatic drugs (including methotrexate) are inappropriate and/or… | Mar 2007 | Recommended with restriction | no section in document |
| adalimumab Treatment of severe, active psoriatic arthritis in patients where the response to previous DMARDs has been inadequate. | Mar 2006 | Recommended with restriction | no section in document |
| infliximab Treatment of severe, active psoriatic arthritis in patients where previous response to disease-modifying antirheumatic drugs (DMARDs) has been inadequate. | Mar 2006 | Recommended with restriction | no section in document |
| adalimumab Treatment of severe, active psoriatic arthritis in patients where the response to previous DMARDs has been inadequate. | Mar 2006 | Recommended with restriction | no section in document |
| infliximab Treatment of severe, active psoriatic arthritis in adults with inadequate response to disease-modifying antirheumatic drugs (DMARDs). | Mar 2006 | Recommended with restriction | no section in document |
Who spoke
Colitis Australia · CreakyJoints Australia · Creaky Joints Australia · Australasian Society of Clinical Immunology and Allergy · Psoriasis Australia · Global Healthy Living Foundation Australia · Musculoskeletal Australia · Australian Rheumatology Association
What the PBS pays
$2,033M in government benefit over 2024–25, across 1,539,667 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| ustekinumab | $538.3M |
| upadacitinib | $291.6M |
| adalimumab | $241.9M |
| guselkumab | $167.6M |
| secukinumab | $120.2M |
| risankizumab | $108.9M |
| golimumab | $97.7M |
| infliximab | $83.8M |
| etanercept | $79.8M |
| ixekizumab | $70M |
| tofacitinib | $57.8M |
| certolizumab pegol | $57.5M |
Appraised elsewhere
NICE, in England and Wales, has appraised 12 technologies for this condition, recommending 11 . A different committee, a different population and a different price: this is what has been looked at there, not a verdict on what happened here.
| Technology | Appraisal | Outcome | Date |
|---|---|---|---|
| bimekizumabBimekizumab for treating active psoriatic arthritis | TA916 | recommended restricted | 2023-10 |
| guselkumabGuselkumab for treating active psoriatic arthritis after inadequate response to DMARDs | TA815 | recommended restricted | 2022-08 |
| risankizumabRisankizumab for treating active psoriatic arthritis after inadequate response to DMARDs | TA803 | recommended restricted | 2022-07 |
| upadacitinibUpadacitinib for treating active psoriatic arthritis after inadequate response to DMARDs | TA768 | recommended restricted | 2022-02 |
| abataceptAbatacept for treating psoriatic arthritis after DMARDs (terminated appraisal) | TA568 | terminated | 2019-03 |
| tofacitinibTofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs | TA543 | recommended restricted | 2018-10 |
| ixekizumabIxekizumab for treating active psoriatic arthritis after inadequate response to DMARDs | TA537 | recommended restricted | 2018-08 |
| certolizumab pegol and secukinumabCertolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs | TA445 | recommended restricted | 2017-05 |
| apremilastApremilast for treating active psoriatic arthritis | TA433 | recommended restricted | 2017-02 |
| ustekinumabUstekinumab for treating active psoriatic arthritis | TA340 | recommended restricted | 2015-06 |
| golimumabGolimumab for the treatment of psoriatic arthritis | TA220 | recommended restricted | 2011-04 |
| etanercept infliximab and adalimumabEtanercept, infliximab and adalimumab for the treatment of psoriatic arthritis | TA199 | recommended | 2010-08 |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 24 of 46 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.